Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization
Immunotherapy in the form of durvalumab and now pembrolizumab alongside chemotherapy is an approved first-line standard of care. Furthermore, it is not uncommon for patients to receive Y90-RE to improve patient outcomes. This report highlights the development of ITP in 2 patients who received durvalumab alongside Y90-RE. Awareness of this as a potential immune-mediated event is important to allow for close monitoring of platelet counts and for early intervention/management when this occurs.
Authors
- Sahrish Khan
- Maaz Khan Afghan
- Benjamin Samstein (ORCID: https://orcid.org/0000-0002-3934-2564)
- Firdausi Qadri (ORCID: https://orcid.org/0000-0001-8459-304X)
- Sana Javaid (ORCID: https://orcid.org/0000-0001-5826-4429)
- Areeb Lutfi
- B. Currie (ORCID: https://orcid.org/0000-0001-6956-8137)
- Pashtoon Murtaza Kasi (ORCID: https://orcid.org/0000-0002-5169-7085)
- Erika Hissong
- Juan Pablo Rocca (ORCID: https://orcid.org/0000-0002-1146-237X)
Institutions
- Cornell University (US)
- Presbyterian Hospital (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1159/000541550
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57